FDA-cleared profile

Tempus Pixel

Arterys, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.

Clinical role
Adjunct image viewer and analysis tool; the FDA labeling says it does not directly generate a diagnosis or finding.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Multi-region
Key limitation
Keep in mind: Requires trained healthcare professionals and user review; optional cardiovascular MR was tested at 1.5T and 3.0T; optional modules and third-party algorithms are not all part of this exact submission.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region Input: DICOM and non-DICOM radiological images, including multi-slice and multi-phase CT, MR, ultrasound, x-ray and mammography studies; optional cardiovascular MR includes velocity-encoded data.
  • Who uses it?Intended users: Trained healthcare professionals, including radiology and cardiovascular imaging users.
  • What does the software produce?Output: Cloud image display with 2D, 3D and MIP views, measurements, reports, secondary capture, optional T1/T2 and 4D-flow cardiovascular MR outputs, and lesion tracking or Lung-RADS reporting workflows.
  • What is its most important limitation?Key limitation: Requires trained healthcare professionals and user review; optional cardiovascular MR was tested at 1.5T and 3.0T; optional modules and third-party algorithms are not all part of this exact submission.

Clinical takeaway. Clinical role: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.

Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed non-clinical T1/T2 inline-map and workflow validation supports the exact release; the FDA summary states there was no clinical study for the modified device.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Adjunct image viewer and analysis tool; the FDA labeling says it does not directly generate a diagnosis or finding.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
DICOM and non-DICOM radiological images, including multi-slice and multi-phase CT, MR, ultrasound, x-ray and mammography studies; optional cardiovascular MR includes velocity-encoded data.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Cloud image display with 2D, 3D and MIP views, measurements, reports, secondary capture, optional T1/T2 and 4D-flow cardiovascular MR outputs, and lesion tracking or Lung-RADS reporting workflows.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Clinical imaging environments using PACS or scanner-originated studies.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained healthcare professionals, including radiology and cardiovascular imaging users.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Requires trained healthcare professionals and user review; optional cardiovascular MR was tested at 1.5T and 3.0T; optional modules and third-party algorithms are not all part of this exact submission.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
FDA-reviewed non-clinical T1/T2 inline-map and workflow validation supports the exact release; the FDA summary states there was no clinical study for the modified device.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-reviewed non-clinical T1/T2 inline-map and workflow validation supports the exact release; the FDA summary states there was no clinical study for the modified device.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

T1/T2 inline map validation

  • DesignNon-clinical comparative bench validation
  • Population30 cardiovascular MR series across manufacturer and scanner types, with four regions of interest per series
  • Scopeexact submission
  • Tested versionTempus Pixel release reviewed in K252539
  • Samplen=30
  • IndependenceSponsor or vendor study

K252539 FDA 510(k) summary

The FDA summary reports software verification and validation passed and states no clinical study was performed for the modified device.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM and non-DICOM radiological images, including multi-slice and multi-phase CT, MR, ultrasound, x-ray and mammography studies; optional cardiovascular MR includes velocity-encoded data.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Tempus Pixel, K252539

  2. Routing

    Source context, not route validation: FDA materials describe upload from PACS or scanner and report/secondary-capture workflows; the Tempus family material was readable during the Sept 7 review and describes PACS, EHR, worklist, notification and dictation integration, but does not establish the exact K252539 configuration. A later automated request returned HTTP 429, which is treated as rate limiting rather than absence of product information.

    Scope: Product family.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · Medical Imaging Cloud AI for Radiology · Tempus Pixel Therapy Response Evaluation

  3. AI processing

    Source context, not route validation: The reviewed FDA summary describes a completely hosted cloud application accessed through Chrome on standard computers and displays.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Tempus Pixel, K252539

  4. Returned objects

    Source context, not route validation: Cloud image display with 2D, 3D and MIP views, measurements, reports, secondary capture, optional T1/T2 and 4D-flow cardiovascular MR outputs, and lesion tracking or Lung-RADS reporting workflows.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Tempus Pixel, K252539

  5. Viewer/worklist/report

    Unresolved route: Cloud image display with 2D, 3D and MIP views, measurements, reports, secondary capture, optional T1/T2 and 4D-flow cardiovascular MR outputs, and lesion tracking or Lung-RADS reporting workflows.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Tempus Pixel, K252539

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The reviewed FDA summary describes a completely hosted cloud application accessed through Chrome on standard computers and displays.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
FDA materials describe upload from PACS or scanner and report/secondary-capture workflows; the Tempus family material was readable during the Sept 7 review and describes PACS, EHR, worklist, notification and dictation integration, but does not establish the exact K252539 configuration. A later automated request returned HTTP 429, which is treated as rate limiting rather than absence of product information.
  • Product family
  • Checked 2026-09-07
Security
Tempus's responsible disclosure policy commits to vulnerability intake for any of its assets (tempus.com and public internet-facing and cloud infrastructure it operates), coordinated handling with a 90-day disclosure window, timely correction, and a safe-harbor commitment for good-faith research. Arterys' own site states Arterys has joined Tempus as Tempus Radiology.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement. Entity bridge: arterys.com announces 'Arterys has joined Tempus... as Tempus Radiology'. The Tempus policy is an organizational vulnerability-handling statement; no certification or audit report was read, and exact-release scope is not established. Applicant name variant 'Arterys, Inc.' is bridged to Arterys, Inc. via the identical distinctive name and Arterys product naming.

Monitoring
Tempus' responsible disclosure policy, covering Tempus assets and operated infrastructure, states vulnerability intake with a 90-day coordinated disclosure window and a timely correction commitment.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The policy names Tempus generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Cloud delivery

The exact FDA summary describes a hosted application accessed through Chrome.

exact submission · checked 2026-09-06

Family PACS and EHR workflow

Current Tempus Pixel family material describes PACS, EHR, worklist, notification and dictation integration; exact K252539 configuration is not established.

product family · checked 2026-09-07

Image and report handling

FDA materials describe 2D/3D/MIP display, measurements, reports and secondary capture outputs.

exact submission · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252539
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

The FDA intended use is multimodality rather than a single anatomic site.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No numeric price was published in the reviewed sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Tempus Pixel Arterys reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

10 sources - 3 history items

Source ledger

  1. K252539 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Tempus Pixel model card (K252539)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision record and summary reviewed for Tempus Pixel, K252539

    U.S. Food and Drug Administration - Published 2025-09-03 - Accessed 2026-09-06

    Scope: identity, intended_use, performance, limitations, implementation

  8. Medical Imaging Cloud AI for Radiology

    Arterys / Tempus - Accessed 2026-09-07

    Scope: product_family, cloud_access, PACS_EHR_workflow

  9. Tempus Pixel Therapy Response Evaluation

    Tempus - Accessed 2026-09-07

    Scope: product_family, lesion_tracking, PACS_EHR_integration

  10. Tempus: Responsible Disclosure Policy

    Tempus Labs - Accessed 2026-10-27

    Scope: security

Research history

  1. K252539 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253270

Contour ProtégéAI+

Mim Software, Inc.

Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K243647

Synapse PACS (7.5)

FUJIFILM Healthcare Americas Corporation

Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-06-30
FDA-cleared K243933

Ceevra Reveal 3+

Ceevra, Inc.

Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-03-04
FDA-cleared K181892

Ziostation2

Ziosoft, Inc.

Authorized purpose: Ziostation2 is customer-hardware image-processing software for viewing, quantifying, manipulating, communicating, printing, and managing many radiological image types, with release-specific tools for lung and bronchoscopy planning, cardiac MR T1 mapping, and other advanced visualization.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2018-10-09

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history